Opus and Viatris Present Phase 3 Phentolamine Data at ASCRS 2026

Overview

• Opus Genetics and Viatris announced multiple ASCRS abstracts on Friday for April 10–13 in Washington, D.C., featuring full VEGA-3 results in presbyopia, an encore LYNX-2 readout in low-light disturbances after refractive surgery, and a MIRA-2 post‑hoc analysis on mydriasis reversal.
• Viatris is funding an independent PRIME symposium titled “Presbyopia Re‑Envisioned: A New Era of Pharmacological Vision Correction,” scheduled for Saturday, April 11 from 6–7:30 p.m. ET at The Westin DC Downtown.
• Opus says a supplemental FDA application to add a presbyopia indication for phentolamine ophthalmic solution 0.75% is under review, alongside an ongoing Phase 3 trial targeting dim‑light, low‑contrast vision problems after keratorefractive procedures.
• Under a global licensing deal, Viatris holds exclusive U.S. rights to commercialize phentolamine ophthalmic solution 0.75%, while Opus leads development and data generation.
• Presbyopia affects about 128 million U.S. adults and an estimated 1.8 billion people worldwide, and night‑vision disturbance was pegged at nearly 55 million across seven major markets in 2023, with many post‑refractive low‑light issues lacking any FDA‑approved treatment.